ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
February 27, 2019 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2019 /PRNewswire/ --
For the full year ended December 31, 2018:
Record net revenues of $201.6 million, an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted GAAP earnings per share of $1.30 Adjusted non-GAAP EBITDA of $84.4 million Adjusted non-GAAP diluted earnings per share of $5.07For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017 GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46 Adjusted non-GAAP EBITDA of $22.2 million... More